FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APP	ROVAL								
OMB Number: 3235-0287									
Estimated average burden									
hours per response:									

Instruction 1(b).	Filed	pursuant to Section 16(a) of the Securities Exchange Act of 1934		Li	nodio poi response.		
· ,		or Section 30(h) of the Investment Company Act of 1940					
1. Name and Address of Reporting Person [*] <u>Lubman Ellen</u>		2. Issuer Name and Ticker or Trading Symbol Werewolf Therapeutics, Inc. [HOWL]		tionship of Rep all applicable)	Reporting Person(s) to Issuer		
		wereworr incrapeaties, me. [now E]		Director		10% Owne	
			$\rfloor_{\mathbf{x}}$	Officer (give	title	Other (spec	
(L) (El) (Mid-l-	I=\	3 Date of Earliest Transaction (Month/Day/Vear)	1 ^	below)		below)	

<u>Lubman Ellen</u>					_ '''	workwort increposition, inc. [now 2]								X	Director Officer (give title		10% Owner Other (specify			
	REWOLF ?	irst) THERAPEUTIC ENUE, 2ND FLO				3. Date of Earliest Transaction (Month/Day/Year) 01/03/2023								X 	below) below) Chief Business Officer					
(Street) WATER	ΓΟWN M		02472 (Zip)		_ 4. l	4. If Amendment, Date of Original Filed (Month/Day/Year)								. Indi ine) X	′					
		Tab	le I - Nor	ı-Deriv	vativ	e Se	curities	s Ac	quired, [Disp	osed c	f, or Be	nefici	ally	Owned					
1. Title of Security (Instr. 3) 2. Trans Date (Month/					action 2A. Deemed Execution Date, if any (Month/Day/Year)			3. Transaction Code (Instr. 8) 4. Securities Acqu Disposed Of (D) (In 5)					5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	V	Amount	(A) or (D) Pi		е	Transact (Instr. 3 a	ion(s)			(311. 4)	
		•	Table II - I						uired, Di , options						wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date,	Code (In		5. Numbor of Derivati Securiti Acquire (A) or Dispose of (D) (II 3, 4 and	ive ies ed ed nstr.	6. Date Exercisa Expiration Date (Month/Day/Yea			7. Title and of Securit Underlying Derivative (Instr. 3 and	ies g Securit	S	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Owner Form Direct or Inc. (I) (In:	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares	er						
Stock Option (right to buy)	\$2.05	01/03/2023			A		86,200		(1)	1:	2/31/2032	Common Stock	86,20	0	\$0.00	86,20	0	D		

Explanation of Responses:

1. The option was granted on January 3, 2023 with a Vesting Commencement Date of January 1, 2023. The shares underlying the option vest in equal monthly installments over four years, commencing on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2027.

Remarks:

Exhibit Index: 24.1 Power of Attorney

/s/ Jonathan Owen, Attorneyin-fact

01/09/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Daniel J. Hicklin, Timothy Trost, Reid Leonard and Jonathan Owen, signing singly and each acting individually, as the undersigned's true and lawful attorney-in-fact with full power and authority as hereinafter described to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or stockholder of Werewolf Therapeutics, Inc. (the "Company"), Forms 3, 4, and 5 (including any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder (the "Exchange Act");
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to prepare, complete and execute any such Form 3, 4, or 5, prepare, complete and execute any amendment or amendments thereto, and timely deliver and file such form with the United States Securities and Exchange Commission (the "SEC") and any stock exchange or similar authority, including, without limitation, the filing of a Form ID, Update Passphrase, or any other application materials to enable the undersigned to gain or maintain access to the Electronic Data Gathering, Analysis and Retrieval system of the SEC;
- (3) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information regarding transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to such attorney-in-fact and approves and ratifies any such release of information; and
- (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming nor relieving, nor is the Company assuming nor relieving, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. The undersigned acknowledges that neither the Company nor the foregoing attorneys-in-fact assume (i) any liability for the undersigned's responsibility to comply with the requirement of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 21st day of January, 2022.

/s/ Ellen Lubman
-----Signature

Ellen Lubman

Print Name